{"result": "(\"entity\"<|>PACIENTES<|>PERSON<|>Patients with cystic fibrosis are individuals affected by the genetic disorder, experiencing various complications including respiratory and nutritional issues.)\n##\n(\"entity\"<|>MORBIMORTALIDAD<|>EVENT<|>Morbimortality refers to the incidence of disease and death associated with cystic fibrosis, particularly affecting women more severely.)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes related to cystic fibrosis is a common complication that increases with age among patients with the disorder.)\n##\n(\"entity\"<|>ALTERACIONES DEL METABOLISMO HIDROCARBONADO<|>EVENT<|>Carbohydrate metabolism disorders are prevalent in cystic fibrosis patients, affecting their overall health and management of the disease.)\n##\n(\"entity\"<|>ÍLEO MECONIAL<|>EVENT<|>Meconium ileus is a condition that occurs in some cystic fibrosis patients, characterized by intestinal obstruction due to thickened meconium.)\n##\n(\"entity\"<|>DESNUTRICIÓN<|>EVENT<|>Malnutrition is a significant concern for cystic fibrosis patients, often resulting from digestive complications and nutrient absorption issues.)\n##\n(\"relationship\"<|>PACIENTES<|>FIBROSIS QUÍSTICA<|>Patients are diagnosed with cystic fibrosis, leading to various health complications<|>9)\n##\n(\"relationship\"<|>PACIENTES<|>DIABETES<|>Diabetes is a common complication that affects patients with cystic fibrosis, particularly as they age<|>7)\n##\n(\"relationship\"<|>PACIENTES<|>ALTERACIONES DEL METABOLISMO HIDROCARBONADO<|>Carbohydrate metabolism disorders are frequently observed in patients with cystic fibrosis<|>6)\n##\n(\"relationship\"<|>PACIENTES<|>DESNUTRICIÓN<|>Malnutrition is a prevalent issue among patients with cystic fibrosis due to their digestive challenges<|>8)\n##\n(\"relationship\"<|>PACIENTES<|>ÍLEO MECONIAL<|>Meconium ileus is a condition that affects some patients with cystic fibrosis, leading to intestinal obstruction<|>5)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>MORBIMORTALIDAD<|>Morbimortality is a significant concern in cystic fibrosis, impacting the health outcomes of affected individuals<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: insufi-\nciencia pancreática exocrina (IPE) está presente en\naproximadamente el 85-90% de los pacientes con FQ\nen las poblaciones de raza blanca . No obstante, esta\nafectación puede descender hasta el 14%, aproxima-\ndamente, en los sujetos diagnosticados en la edad\nadulta (mayores de 16 años). Por ello en series de\nadultos, donde entre el 20 y el 30% de los mismos\nhan sido diagnosticados en edad adulta, la prevalen-\ncia de IPE es menor que la descrita previamente y se\nencuentra alrededor del 70%2. La prevalencia de dia-\nbetes relacionada con la FQ aumenta con la edad19, 20.\nEn nuestro grupo, la prevalencia de alteraciones del\nmetabolismo hidrocarbonado (con una edad media\nde 29 años) ha sido de un 42%, con un 36% de dia-\nbetes relacionada con la FQ. Estas alteraciones se aso-\ncian a un deterioro de la función pulmonar y a un\naumento en la morbimortalidad en la FQ, más eviden-\nte en mujeres, y suponen un marcador más de pro-\ngresión de la enfermedad.\n\nA diferencia de la patología respiratoria, la afecta-\nción hepática clínica es mucho menos prevalente. La\nincidencia de insuficiencia hepática grave se incremen-\nta en la niñez tardía hasta la adolescencia, siendo rara\nla aparición después de los 18 años de edad. La afecta-\nción patológica típica es la cirrosis biliar focal que, si\nprogresa, puede desarrollar cirrosis biliar multilobular e\nhipertensión portal con sus complicaciones subsecuen-\ntes en aproximadamente el 5 al 10% de los sujetos. La\nesteatosis también se ha descrito en hasta el 67% de los\npacientes con FQ, generalmente asociada a desnutrición\nsevera o a déficits nutricionales específicos (de ácidos\ngrasos esenciales, carnitina o colina) (tabla 3)17, 21.\nOtras alteraciones digestivas condicionan desnutrición.\nAproximadamente el 5% de los pacientes nacen con\níleo meconial, que es una obstrucción intestinal se-\ncundaria al espesamiento del meconio en el íleo termi-\nnal. Ocurre en el 20-25% de los pacientes con fenotipo\nclásico y es un signo de enfermedad y genotipos gra-\nves. Su tratamiento puede condicionar resecciones in-\ntestinales que agravan el riesgo de desnutrición a largo\nplazo, incluyendo el déficit de vitamina B12. También,\nlos pacientes con FQ tienen una prevalencia aumenta-\nda de reflujo gastroesofágico (RGE) y hasta el 80%\npuede tener pirosis y el 56% dispepsia22, 23. El síndro-\nme de obstrucción intestinal distal (SOID) es una\nforma de obstrucción parcial crónica y recurrente del\nintestino que ocurre frecuentemente en pacientes con\nFQ y casi exclusivamente con IPE. Se produce por la\nobstrucción parcial (rara vez total) de la luz por conte-\nnido intestinal mucofecaloideo viscoso en el íleon ter-\nminal y/o colon proximal. La incidencia de obstrucción\ntotal en niños es de 5 a 12 episodios por 1.000 pacien-\ntes y año. La incidencia de obstrucción parcial en adul-\n---\nTema 35. Soporte nutricional en el paciente con patología pulmonar, enfermedad pulmonar... 557\n\nTabla 3. Complicaciones hepatobiliares en fibrosis quística.\n\n| Complicaciones | Prevalencia (%) |\n|-----------------|-----------------|\n| Esteatosis hepática | 20-60 |\n| Cirrosis biliar focal | 20-30 |\n| Cirrosis multilobular | 5-10 |\n| Hipertensión portal | 2-5 |\n| Microvesícula | 5-20 |\n| Distensión vesicular | 3-20 |\n| Micro litiasis y barro biliar | 30 |\n| Colelitiasis | 15 |\n| Esteatosis hepática (de origen yatrógeno generalmente) | 25-60 |\n\nModificada de Debray D17.\n\nFVC) tras broncodilatación es menor de 0,7 (o debajo del límite inferior de la normalidad en personas mayores de 60 años).\n\nPara completar el estudio pueden ser útiles otras pruebas adicionales como la pulsioximetría, gasometría arterial, análisis de sangre y orina, electrocardiograma, o la determinación de alfa-1 antitripsina sérica. Por último, existen otras pruebas opcionales, en función de la clínica, como el test de difusión, la pletismografía, la determinación de la distensibilidad pulmonar, el test de la marcha de 6 o\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>FIBROSIS QUÍSTICA<|>EVENT<|>Fibrosis quística (FQ) is a genetic disorder that affects the lungs and digestive system, leading to severe respiratory and nutritional complications.)\n##\n(\"entity\"<|>INSUFICIENCIA PANCREÁTICA EXOCRINA<|>EVENT<|>Exocrine pancreatic insufficiency (IPE) is a condition present in a significant percentage of patients with cystic fibrosis, affecting their ability to digest food properly.)\n##\n(\"entity\"<|>CIRROSIS BILIAR FOCAL<|>EVENT<|>Focal biliary cirrhosis is a liver condition that can develop in patients with cystic fibrosis, characterized by damage to the bile ducts.)\n##\n(\"entity\"<|>HIPERTENSIÓN PORTAL<|>EVENT<|>Portal hypertension is a complication that can arise from liver diseases such as biliary cirrhosis in cystic fibrosis patients.)\n##\n(\"entity\"<|>ESTEATOSIS HEPÁTICA<|>EVENT<|>Hepatic steatosis is a condition where fat accumulates in the liver, which can occur in cystic fibrosis patients, often associated with severe malnutrition.)\n##\n(\"entity\"<|>REFLUJO GASTROESOFÁGICO<|>EVENT<|>Gastroesophageal reflux disease (GERD) is a common condition in cystic fibrosis patients, leading to symptoms like heartburn and indigestion.)\n##\n(\"entity\"<|>SÍNDROME DE OBSTRUCCIÓN INTESTINAL DISTAL<|>EVENT<|>Distal intestinal obstruction syndrome (DIOS) is a complication in cystic fibrosis characterized by partial bowel obstruction due to thickened intestinal contents.)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>INSUFICIENCIA PANCREÁTICA EXOCRINA<|>Exocrine pancreatic insufficiency is a common complication in patients with cystic fibrosis, affecting their digestion<|>8)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>CIRROSIS BILIAR FOCAL<|>Biliary cirrhosis can develop as a liver complication in patients suffering from cystic fibrosis<|>6)\n##\n(\"relationship\"<|>CIRROSIS BILIAR FOCAL<|>HIPERTENSIÓN PORTAL<|>Portal hypertension can occur as a result of complications from biliary cirrhosis in cystic fibrosis patients<|>5)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>ESTEATOSIS HEPÁTICA<|>Hepatic steatosis is often associated with malnutrition in cystic fibrosis patients<|>6)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>REFLUJO GASTROESOFÁGICO<|>Gastroesophageal reflux disease is frequently observed in patients with cystic fibrosis<|>7)\n##\n(\"relationship\"<|>FIBROSIS QUÍSTICA<|>SÍNDROME DE OBSTRUCCIÓN INTESTINAL DISTAL<|>Distal intestinal obstruction syndrome is a common gastrointestinal complication in cystic fibrosis<|>7)\n<|COMPLETE|>"}]}